What is QuantuMDx Group?
QuantuMDx Group operates at the intersection of biotechnology and clinical diagnostics, specializing in rapid multiplex PCR solutions designed for point-of-care testing. The company's flagship innovation, the Q-POC platform, represents a paradigm shift in diagnostic speed and accuracy, delivering actionable results in approximately 30 minutes. By decentralizing laboratory-grade testing, QuantuMDx empowers healthcare professionals and clinical managers to make informed decisions at the bedside, thereby optimizing patient outcomes and operational efficiency in diverse healthcare settings worldwide.
How much funding has QuantuMDx Group raised?
QuantuMDx Group has raised a total of $39.6M across 5 funding rounds:
Grant
$1.6M
Unspecified
$8.4M
Private Equity
$2.5M
Unspecified
$12M
Debt
$15.1M
Grant (2013): $1.6M, investors not publicly disclosed
Unspecified (2014): $8.4M, investors not publicly disclosed
Private Equity (2016): $2.5M supported by Helsinn Investment Fund
Unspecified (2018): $12M, investors not publicly disclosed
Debt (2021): $15.1M, investors not publicly disclosed
Key Investors in QuantuMDx Group
Helsinn Investment Fund
A Luxembourg-based investment vehicle owned by the Helsinn Group, focusing on early-stage opportunities in areas of high unmet patient need, including cancer therapeutics and diagnostics.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for QuantuMDx Group?
With the recent infusion of capital, QuantuMDx is poised to transition into a phase of rapid commercial expansion and technological refinement. The strategic focus will likely center on scaling the manufacturing and distribution of the Q-POC platform to meet the surging global demand for decentralized diagnostic tools. Furthermore, the company is expected to invest in expanding its multiplex testing capabilities, potentially broadening its diagnostic portfolio to address a wider array of clinical conditions. As the firm continues to integrate into international healthcare infrastructures, its ability to maintain high-quality diagnostic standards while scaling will be the primary determinant of its long-term market leadership.
See full QuantuMDx Group company page
